How Has The Size And Value Of The Pharmacogenomics Market Changed During The 2026–2030 Period?
The pharmacogenomics market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $10.85 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing genomic research activities, expansion of targeted therapy development, rising prevalence of chronic diseases, improvements in sequencing technologies, growing availability of genetic testing services.
The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising adoption of AI-driven genomic analysis, expansion of pharmacogenomics in oncology and cardiology, growing focus on individualized drug development, continuous advancements in bioinformatics platforms. Major trends in the forecast period include increasing adoption of personalized medicine approaches, rising use of genetic testing in drug selection, growing integration of pharmacogenomic data in clinical workflows, expansion of companion diagnostics, enhanced focus on precision therapeutics.
Claim Your Free Report Sample Today:
What Fundamental Drivers Are Expected To Boost The Pharmacogenomics Market Throughout The Forecast Period?
The increasing number of chronic diseases is expected to propel the growth of the pharmacogenomics market going forward. Chronic diseases are medical conditions that persist over an extended period, often for a person's lifetime. The rise in chronic diseases is due to the increasing average lifespan of the global population and the widespread adoption of behavioral risk factors such as sedentary lifestyles, poor diet, and tobacco use. Pharmacogenomics offers a personalized approach to the treatment of chronic diseases, taking into account individual genetic variations that impact drug response. For instance, in 2025, according to the International Diabetes Federation, a Belgium-based health organization, in 2024, around 589 million adults aged 20-79 were living with diabetes, with the total number projected to reach 853 million by 2050 and with more than 4 in 5 adults with diabetes residing in low and middle income countries. Therefore, the increasing number of chronic diseases is driving the growth of the pharmacogenomics market.
What Are The Key Segmentation Components That Define The Structure Of The Pharmacogenomics Market?
The pharmacogenomics market covered in this report is segmented –
1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
Subsegments:
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing
2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR
3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)
5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays
6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools
Which Rising Trends Are Anticipated To Influence The Future Trajectory Of The Pharmacogenomics Market?
Major companies operating in the pharmacogenomics market are increasingly focusing on artificial intelligence (AI) driven models that manage drug-drug interactions (DDIs) at the genomic level, thereby improving medication safety, reducing adverse reactions, and enabling highly personalized prescribing. AI-powered pharmacogenetics engines refer to advanced digital systems that use artificial intelligence to analyze a person’s genetic profile and predict how they will respond to specific medications. For example, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, launched its Sirius model, an AI-powered pharmacogenetics engine that personalizes drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius covers 730 drugs and 40 key pharmacogenes, enabling much broader coverage than traditional pharmacogenomic solutions. The model is designed to be used by hospital systems, diagnostic labs, and clinical research organizations, helping to reduce adverse reactions and improve therapeutic outcomes.
Who Are The Standout Companies Known For Innovation In The Pharmacogenomics Market?
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos
Get Your In-Depth Pharmacogenomics Market Report Now:
Which Regions Stand Out As Major Contributors To Future Demand In The Pharmacogenomics Market?
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment